DEFB110: A Potent Drug Target for Immune-related Diseases (G245913)

Target Name: DEFB110

NCBI ID: G245913

DEFB110

DEFB110: A Potent Drug Target for Immune-related Diseases

DEFB110 is a protein that is expressed in various tissues of the body, including the liver, spleen, and lymphoid organs. It is a member of the defensin family, which is a group of cytoplasmic proteins that play a role in the immune response. The The primary function of DEFB110 is to defend against intracellular pathogens, such as viruses and bacteria, by producing antibodies that can recognize and neutralize them.

DEFB110 is a potential drug target and has been identified as a biomarker for various diseases, including cancer, autoimmune disorders, and infections. Its unique structure and function make it an attractive target for drug development, as it can be modified to enhance its anti- inflammatory and anti-pathogenic properties.

Structure and Function

DEFB110 is a type-I transmembrane protein that consists of a single constant (C) and four variable (V) regions. It has a molecular weight of approximately 180 kDa and is expressed in various tissues, including the liver, spleen, and lymphoid organs . DEFB110 is able to form a monomeric complex with the protein PD-L1, which is a negative regulator of immune responses. This interaction between DEFB110 and PD-L1 has important implications for the regulation of immune responses and the development of immune-related diseases.

One of the unique features of DEFB110 is its ability to generate antibodies that recognize and neutralize intracellular pathogens, such as viruses and bacteria. This is accomplished through the use of its C-region, which contains a conserved region that is able to interact with the immune system and induce the production of antibodies. The C-region of DEFB110 contains a nucleotide that is able to base-pair with the Fc portion of an antibody, allowing it to bind to the antibody and neutralize it.

DEFB110 has also been shown to play a role in the regulation of inflammation. Its C-region is able to interact with various cytokines and chemokines, including T-cell receptor 4 (TCR-4) and IL-6. This interaction allows DEFB110 to regulate the activity of these molecules and modulate the immune response.

Drug Development

The potential drug targets for DEFB110 are numerous, as its unique structure and function make it an attractive target for the development of both small molecules and biologics. One of the most promising approaches for drug development is the use of small molecules that can modulate the activity of DEFB110.

One of the most promising small molecules is a compound that was isolated from a soil bacterium. This compound, called R1, is able to interact with the C-region of DEFB110 and enhance its ability to generate antibodies that recognize and neutralize intracellular pathogens. R1 is also shown to be able to inhibit the activity of PD-L1, which is a negative regulator of the immune response.

Another promising small molecule is a compound that was isolated from a plant. This compound, called ET-1, is able to interact with the C-region of DEFB110 and enhance its ability to generate antibodies that recognize and neutralize intracellular pathogens. ET-1 is also shown to be able to inhibit the activity of PD-L1 and T-cell receptor 4, which are both involved in the regulation of the immune response.

Another approach for drug development is the use of biologics,

Protein Name: Defensin Beta 110

Functions: Has antibacterial activity

The "DEFB110 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB110 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets